[go: up one dir, main page]

SE9002731D0 - Product comprising growth factor - Google Patents

Product comprising growth factor

Info

Publication number
SE9002731D0
SE9002731D0 SE9002731A SE9002731A SE9002731D0 SE 9002731 D0 SE9002731 D0 SE 9002731D0 SE 9002731 A SE9002731 A SE 9002731A SE 9002731 A SE9002731 A SE 9002731A SE 9002731 D0 SE9002731 D0 SE 9002731D0
Authority
SE
Sweden
Prior art keywords
pct
nutrient
product
growth factor
date mar
Prior art date
Application number
SE9002731A
Other languages
English (en)
Inventor
L Fryklund
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20380208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9002731(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Priority to SE9002731A priority Critical patent/SE9002731D0/sv
Publication of SE9002731D0 publication Critical patent/SE9002731D0/sv
Priority to IE261591A priority patent/IE912615A1/en
Priority to PCT/SE1991/000557 priority patent/WO1992003154A1/en
Priority to EP91915377A priority patent/EP0546007B2/en
Priority to DE69124382T priority patent/DE69124382T3/de
Priority to DK91915377.5T priority patent/DK0546007T3/da
Priority to ES91915377T priority patent/ES2097816T5/es
Priority to AT91915377T priority patent/ATE147988T1/de
Priority to AU84488/91A priority patent/AU650050B2/en
Priority to CA002088674A priority patent/CA2088674A1/en
Priority to JP3514401A priority patent/JP2521867B2/ja
Priority to US07/979,863 priority patent/US6034059A/en
Priority to PT98764A priority patent/PT98764B/pt
Priority to GR970400622T priority patent/GR3022935T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SE9002731A 1990-08-24 1990-08-24 Product comprising growth factor SE9002731D0 (sv)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE9002731A SE9002731D0 (sv) 1990-08-24 1990-08-24 Product comprising growth factor
IE261591A IE912615A1 (en) 1990-08-24 1991-07-24 Product and use of it for the treatment of catabolic states¹comprising authentic igf-1 and hypocaloric amount of¹nutrients
US07/979,863 US6034059A (en) 1990-08-24 1991-08-22 Treatment of catabolic states using authentic IGF-1 and hypocaloric amount of nutrients
JP3514401A JP2521867B2 (ja) 1990-08-24 1991-08-22 オ―センティックｉｇｆ―１と発熱量の栄養分とからなる異化状態の治療用の組成物
DK91915377.5T DK0546007T3 (da) 1990-08-24 1991-08-22 Produkt, og anvendelse heraf til behandling af kataboliske tilstande, omfattende autentisk IGF-1 og hypokaloriske mængder af næringsmidler
EP91915377A EP0546007B2 (en) 1990-08-24 1991-08-22 Product and use of it for the treatment of catabolic states comprising authentic igf-1 and hypocaloric amount of nutritients
DE69124382T DE69124382T3 (de) 1990-08-24 1991-08-22 Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
PCT/SE1991/000557 WO1992003154A1 (en) 1990-08-24 1991-08-22 Product and use of it for the treatment of catabolic states comprising authentic igf-1 and hypocaloric amount of nutritients
ES91915377T ES2097816T5 (es) 1990-08-24 1991-08-22 Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes.
AT91915377T ATE147988T1 (de) 1990-08-24 1991-08-22 Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
AU84488/91A AU650050B2 (en) 1990-08-24 1991-08-22 Product and use of it for the treatment of catabolic states comprising authentic IGF-1 and hypocaloric amount of nutritients
CA002088674A CA2088674A1 (en) 1990-08-24 1991-08-22 Product and use of it for the treatment of catabolic states comprising authentic igf-1 and hypocaloric amount of nutrients
PT98764A PT98764B (pt) 1990-08-24 1991-08-23 Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos
GR970400622T GR3022935T3 (en) 1990-08-24 1997-03-26 Product and use of it for the treatment of catabolic states comprising authentic igf-1 and hypocaloric amount of nutritients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9002731A SE9002731D0 (sv) 1990-08-24 1990-08-24 Product comprising growth factor

Publications (1)

Publication Number Publication Date
SE9002731D0 true SE9002731D0 (sv) 1990-08-24

Family

ID=20380208

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9002731A SE9002731D0 (sv) 1990-08-24 1990-08-24 Product comprising growth factor

Country Status (14)

Country Link
US (1) US6034059A (sv)
EP (1) EP0546007B2 (sv)
JP (1) JP2521867B2 (sv)
AT (1) ATE147988T1 (sv)
AU (1) AU650050B2 (sv)
CA (1) CA2088674A1 (sv)
DE (1) DE69124382T3 (sv)
DK (1) DK0546007T3 (sv)
ES (1) ES2097816T5 (sv)
GR (1) GR3022935T3 (sv)
IE (1) IE912615A1 (sv)
PT (1) PT98764B (sv)
SE (1) SE9002731D0 (sv)
WO (1) WO1992003154A1 (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
ATE495443T1 (de) 2000-11-28 2011-01-15 Premacure Ab Reduzierung des risikos für komplikationen bei frühgeburten
JP3896879B2 (ja) * 2002-03-22 2007-03-22 日本電気株式会社 トラヒック監視システム
EP1901770B1 (en) * 2005-06-02 2014-12-24 Ipsen Biopharmaceuticals, Inc. Gh and igf-1 for treatment of growth disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598205B2 (en) * 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
EP0288478B1 (en) * 1986-01-09 1992-08-19 Brigham And Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
EP0303746B2 (en) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
EP0346429B1 (en) * 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)

Also Published As

Publication number Publication date
CA2088674A1 (en) 1992-02-25
GR3022935T3 (en) 1997-06-30
EP0546007A1 (en) 1993-06-16
ES2097816T3 (es) 1997-04-16
JP2521867B2 (ja) 1996-08-07
DE69124382D1 (de) 1997-03-06
PT98764A (pt) 1993-09-30
DE69124382T3 (de) 2003-09-11
JPH05509323A (ja) 1993-12-22
AU8448891A (en) 1992-03-17
ES2097816T5 (es) 2003-07-16
EP0546007B2 (en) 2003-01-29
IE912615A1 (en) 1992-02-26
ATE147988T1 (de) 1997-02-15
EP0546007B1 (en) 1997-01-22
DE69124382T2 (de) 1997-06-26
US6034059A (en) 2000-03-07
AU650050B2 (en) 1994-06-09
DK0546007T3 (da) 1997-03-17
PT98764B (pt) 1999-01-29
WO1992003154A1 (en) 1992-03-05

Similar Documents

Publication Publication Date Title
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DE69120430D1 (de) Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
ATE188609T1 (de) Befruchtete muscheleier enthaltende zusammensetzung
ATE126972T1 (de) Formulierung zur behandlung von silage.
NO931766D0 (no) Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
MY106528A (en) Method of treating impotence.
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
ATE108658T1 (de) Verwendung von tetracycline zur herstellung eines arzneimittels zum herabsetzen des augendrucks.
SE9002731D0 (sv) Product comprising growth factor
TW261532B (sv)
LTIP1534A (en) Medicinal preparations for prophylaxis and treating metabolic disturbance of lipoids and cholesterin
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69315840D1 (de) Verfahren zur verabreichung einer lösung von granulozyten-kolonie-stimulierendem faktor
UA40974A (uk) Спосіб лікування міопії у дітей та підлітків
GR3027682T3 (en) 4-guanidinobutyramide for improving blood circulation.
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen